MAM
Dhoni named brand ambassador to promote BPL
NEW DELHI: Indian skipper M S Dhoni has been appointed brand ambassador to promote Barclays Premier League football (BPL) in India by Star Sports.
A keen football enthusiast and a Manchester United fan, Dhoni will invite all sports fans to ‘Join the Game‘ in a clutter breaking integrated marketing campaign which will be launched early next week. The campaign will have a strong on-air and digital media thrust.
 |
This announcement comes on the back of the sports broadcaster announcing the launch of Hindi commentary for the first time on BPL. The Hindi commentary will be in addition to the English commentary and will be available for over 100 live matches across the season.
Speaking on the occasion, ESPN Software India COO Vijay Rajput said, “We are delighted to have MS Dhoni come on board as the brand ambassador for BPL in the country. We are targeting to expand the fan base of BPL in India by leveraging the iconic power and fan following of MS Dhoni to attract cricket fans to sample BPL – Duniya ka sabse bada league. We want these fans to sample matches of BPL through the eyes of their biggest hero. The core campaign idea is ‘Join the Game‘. The launch of BPL in Hindi is in line with our overall strategy of pushing multi-lingual content. We believe that if you want people to consume a lot of content, you should offer it to them in their language of comfort.”
The BPL campaign will build on Dhoni‘s love for football. He will invite sports fans in India to ‘Join the Game‘. The campaign has interesting renditions of how Dhoni is always missing from action and is glued to the TV sets watching BPL every weekend while his family and friends run around looking for him.
Speaking on the association, Dhoni said, “I am an avid BPL fan and I just played out a real situation in front of the camera. If I am not busy with cricket, I am always busy with BPL during week-ends. Football is extremely exciting and very close to my heart. I was a goal keeper during my school days. Even today, I play football as a warm up game ahead of key cricket matches.”
“I feel that Indian sports fans should consume different types of sports. I want them to be passionate about Cricket as they are, but at the same time one needs to give healthy respect for other disciplines as well. It is critical to spread the message of overall sports development and promotion in the country. This Star Sports initiative to provide football commentary now in Hindi will go a long way in making football exciting to watch and comprehend for new audiences across the nation. Similar efforts should be done to promote other sports as well,” India‘s captain added.
Star Sports has aggressive production plans for non-live programming on this season of BPL in Hindi. The support of non-live programming through the season will play a key role in educating consumers about the league. The broadcaster plans to showcase highlight shows, weekly show based on ‘goals‘; and a weekly magazine show which will review and preview the latest developments from BPL. The sports channel has started off non-live programming with a six episode build-up show ‘Superstar Football‘ which focuses on multiple facets of the league – famous owners, top clubs, top players etc.
In football, Star Sports channels hold broadcast rights for Barclays Premier League, Spanish La Liga, Italian Serie A, the English FA Cup and England international matches and AFC Events. Star Sports has recently showcased FIFA Confederations Cup 2013.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
